

Synthesis of Novel  
3-Carboethoxy-6-methyl-4-oxo-4*H*-pyrimido[1',2':5,6]-  
[1,3,5]triazino[1,2-*a*]benzimidazoles [1]

M. S. R. Murty, T. Ramalingam\* and P. B. Sattur

Indian Institute of Chemical Technology,  
Hyderabad 500 007, India  
Received August 8, 1989

Reaction of 4-amino-2-methylbenzimidazo[1,2-*a*][1,3,5]triazines **2** with diethyl ethoxymethylenemalonate afforded 3-carboethoxy-6-methyl-4-oxo-4*H*-pyrimido[1',2':5,6][1,3,5]triazino[1,2-*a*]benzimidazoles **3**, a new ring system.

*J. Heterocyclic Chem.*, **27**, 949 (1990).

Derivatives of benzimidazoles [2], 1,3,5-triazines [3] and pyrimidines [4] occupy a conspicuous place in the domain of heterocyclic chemistry in view of their broad spectrum biological activity exhibited by these compounds as drugs. Sometimes the fusion of heterocyclic nuclei resulting in polyheterocyclic compounds enhances the biological pro-

file many fold more than its parent nucleus. In our program in the novel fused pyrimidines, we recently described the synthesis of some 2-substituted 6-carboethoxy-5-oxo-5*H*-1,3,4-oxodiazolo[4,5-*a*]pyrimidines [5] and 3-carboethoxy-4,11-dihydro-11-alkyl/phenyl-4-oxopyrimido[1,2-*b*][1,2,4]benzothiadiazine-6,6-dioxides [6]. These find-

Scheme




Table 1

No.	R <sub>1</sub>	R <sub>2</sub>	mp °C	Yield (%)	Molecular Formula	Analysis (%)			M <sup>+</sup> (m/e)
						Calcd.	Found		
						C	H	N	
2a	H	H	293-295 [a]	74	C <sub>10</sub> H <sub>9</sub> N <sub>5</sub>				199
2b	CH <sub>3</sub>	CH <sub>3</sub>	278-279	80	C <sub>12</sub> H <sub>13</sub> N <sub>5</sub>	63.42	5.76	30.82	227
						63.19	5.80	31.10	
2c	C <sub>6</sub> H <sub>5</sub> CO	H	191-193	79	C <sub>17</sub> H <sub>13</sub> N <sub>5</sub> O	67.32	4.32	23.09	303
						67.08	4.40	23.19	
2d	Cl	H	256-259	65	C <sub>10</sub> H <sub>8</sub> ClN <sub>5</sub>	51.41	3.45	29.97	233
						51.52	3.50	29.78	
3a	H	H	205-206	78	C <sub>16</sub> H <sub>13</sub> N <sub>5</sub> O <sub>3</sub>	59.44	4.05	21.66	323
						59.80	4.00	21.70	
3b	CH <sub>3</sub>	CH <sub>3</sub>	185-188	80	C <sub>18</sub> H <sub>17</sub> N <sub>5</sub> O <sub>3</sub>	61.53	4.88	19.93	351
						61.60	4.81	20.00	
3c	C <sub>6</sub> H <sub>5</sub> CO	H	241-244	79	C <sub>23</sub> H <sub>17</sub> N <sub>5</sub> O <sub>4</sub>	64.63	4.01	16.39	427
						64.50	4.09	16.44	
3d	Cl	H	227-229	68	C <sub>16</sub> H <sub>12</sub> ClN <sub>5</sub> O <sub>3</sub>	53.72	3.38	19.57	357
						53.90	3.41	19.45	

[a] Lit [7] mp 293-295.

ings prompted us to make efforts to develop a synthetic route leading to pyrimido[1',2':5,6][1,3,5]triazino[1,2-*a*]-benzimidazoles, a novel ring system which possess pyrimidine, triazine and benzimidazole moieties in a single molecule.

Ethyl *N*-cyanoacetimidate has been shown to interact with 2-aminobenzimidazole (**1a**) to give 4-amino-2-methylbenzimidazole[1,2-*a*][1,3,5]triazine (**2a**) [7]. In the present work, compounds **2b-d** (Table 1) were synthesized for the first time by the reaction of 2-amino-5,6-substituted benzimidazoles **1b-d** with ethyl *N*-cyanoacetimidate in 65-80% yields employing the literature procedure [7].

Diethyl ethoxymethylenemalonate (EMME) as a synthon [8] has attracted considerable interest on account of its versatility as a reagent in the development of various heterocyclic systems [9-11]. We report herein a facile synthesis of compounds **3a-d** (Table 1), an entirely new class of tetracyclic ring system in 68-80% yields by condensing **2a-d** and EMME in refluxing dimethylformamide for 6 hours in a single step (Scheme). Ethyl *N*-cyanoacetimidate was made as reported [12].

The characterisation of **2b-d** and **3a-d** is based on elemental analyses and spectroscopic data.

#### EXPERIMENTAL

Melting points were determined on Buchi 510 apparatus and are uncorrected. Infrared (ir) spectra were recorded with a Perkin Elmer 221 spectrophotometer. The <sup>1</sup>H nmr spectra have been obtained with a Varian FT-80A spectrometer using TMS as an internal standard. Mass spectra were recorded on VG micromass 70-70H mass spectrometer at 70 eV.

Typical Reaction Procedure.

4-Amino-2,7,8-trimethylbenzimidazo[1,2-*a*][1,3,5]triazine (**2b**).

A mixture of 2-amino-5,6-dimethylbenzimidazole (1.61 g, 0.01 mole), ethyl *N*-cyanoacetimidate (2.24 g, 0.02 mole) and dimethoxyethane (20 ml) was refluxed for 1 hour with stirring. After cooling, the precipitate was filtered and recrystallised from dimethylformamide to give **2b**; ir (potassium bromide): 3130, 1650

and 1540 cm<sup>-1</sup>; <sup>1</sup>H nmr (dimethyl sulfoxide-*d*<sub>6</sub>): δ 7.7 (s, 2H, 6- and 9-H), 6.7 (broad, 2H, NH<sub>2</sub>, deuterium oxide-exchangeable), 2.6 (s, 3H, 2-CH<sub>3</sub>), 2.5 (s, 6H, 7- and 8-CH<sub>3</sub>).

3-Carboethoxy-6,10,11-trimethyl-4-oxo-4*H*-pyrimido[1',2':5,6]-[1,3,5]triazino[1,2-*a*]benzimidazole (**3b**).

A solution of 4-amino-2,7,8-trimethylbenzimidazo[1,2-*a*][1,3,5]triazine (2.27 g, 0.01 mole) and diethyl ethoxymethylenemalonate (2.16 g, 0.01 mole) in dimethyl formamide (40 ml) was refluxed for 6 hours with stirring and was concentrated under reduced pressure. The concentrated solution was poured into ice cold water. The residue formed was filtered, washed with water and recrystallised from ethanol to give **3b**; ir (potassium bromide): 1700, 1640 and 1580 cm<sup>-1</sup>; <sup>1</sup>H nmr (dimethyl sulfoxide-*d*<sub>6</sub>): δ 9.0 (s, 1H, 2-H), 7.8 (s, 2H, 9- and 12-H), 4.4 (q, 2H, CH<sub>2</sub>, J = 7 Hz), 2.6 (s, 3H, 6-CH<sub>3</sub>), 2.5 (s, 6H, 10- and 11-CH<sub>3</sub>), 1.4 (t, 3H, CH<sub>2</sub>CH<sub>3</sub>, J = 7 Hz).

Acknowledgement.

The authors are grateful to Prof. Kurt L. Loening, Chemical Abstracts Service for providing nomenclature of the ring system.

#### REFERENCES AND NOTES

- [1] IICT Communication No. 2398.
- [2] J. L. H. Van Gelder, A. H. M. Raeymaekers and L. F. C. Roevens, German Patent 2,029,637 (1971); *Chem. Abstr.*, **74**, 100,047s (1971).
- [3] E. J. Modest, *J. Org. Chem.*, **21**, 1 (1956).
- [4] J. Castaner, *Drugs of the Future*, **11**, 383 (1977).
- [5] M. S. R. Murty, T. Ramalingam, P. V. Diwan and P. B. Sattur, *Ind. J. Chem.*, **27B**, 293 (1988).
- [6] M. S. R. Murty, Y. V. D. Nageswar, A. V. N. Reddy, T. Ramalingam and P. B. Sattur, *J. Heterocyclic Chem.*, **26**, 473 (1989).
- [7] I. Lalezari and S. Nabahi, *J. Heterocyclic Chem.*, **17**, 1121 (1980).
- [8] W. P. William and J. K. Thomas, in *Advances in Heterocyclic Chemistry*, Vol **11**, A. R. Katritzky and A. J. Boulton, eds, Academic Press, New York, 1970, p 139.
- [9] H. Koga, A. Itoh, S. Murayama, S. Suzue and T. Irikura, *J. Med. Chem.*, **23**, 1358 (1980).
- [10] G. R. Lappin, *J. Am. Chem. Soc.*, **70**, 3348 (1948).
- [11] B. H. Rizkalla and A. D. Broom, *J. Org. Chem.*, **37**, 3980 (1972).
- [12] K. R. Huffman and F. C. Schaefer, *J. Org. Chem.*, **28**, 1816 (1963).